Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma group ...
Johnson & Johnson's Tecvayli has been approved as part of a combination regimen with its Genmab-partnered Darzalex Faspro as a second-line therapy for relapsed or refractory multiple myeloma, just 55 ...
Primary progressive multiple sclerosis (PPMS) can cause symptoms like difficulty walking, vision changes, and trouble focusing. With workplace accommodations and symptom management, many people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results